Rank: 2 | Score: 82/100
Microglia-State Editing via TREM2 Pulse Program is a sophisticated therapeutic approach that uses staged pharmacologic intervention to reprogram microglia from a disease-associated inflammatory state to a protective, repair-competent phenotype. The protocol combines TREM2 activation with Liver X Receptor (LXR) agonism in a temporal sequencing pattern designed to maximize neuroprotection while minimizing risks[1][2][3].
Microglia exist on a spectrum of activation states:
Disease-Associated Microglia (DAM)[5]
Neuroprotective Microglia (NPM)
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is critical for microglial function:
Liver X Receptors are nuclear receptors that regulate lipid metabolism:
The pulse program concept addresses:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | Novel combination of TREM2 + LXR pulsing; not in clinical development |
| Mechanistic Rationale | 10 | Strong scientific basis for both targets and their sequencing |
| Root-Cause Coverage | 9 | Addresses microglial dysfunction, a core pathological mechanism |
| Delivery Feasibility | 7 | Requires biologics for TREM2; LXR agonists in development |
| Safety Plausibility | 7 | Complex immune modulation requires careful monitoring |
| Combinability | 9 | Excellent synergy with anti-amyloid and anti-tau approaches |
| Biomarker Availability | 7 | sTREM2 and lipid markers can serve as pharmacodynamic markers |
| De-risking Path | 7 | Novel mechanism with acceptable risk profile |
| Multi-disease Potential | 9 | Relevant to AD, PD, ALS, and FTD |
| Patient Impact | 9 | Could significantly improve microglial function and disease outcomes |
| Trial ID | Compound | Phase | Sample Size | Population | Primary Endpoint | Key Results |
|---|---|---|---|---|---|---|
| NCT04449847 | ADC-1004 (TREM2 agonist) | Phase 1 | 72 | Healthy volunteers | Safety, PK | Completed; favorable safety profile |
| NCT05157082 | AL002 (TREM2 agonist) | Phase 2 | 265 | Early AD | ADAS-Cog14, CDR-SB | Ongoing; sTREM2 engagement observed |
| NCT05694819 | AL002c | Phase 1 | 48 | Healthy volunteers | Safety, PK | Recruiting |
| NCT05420160 | HWH340 (TREM2 antibody) | Phase 1 | 36 | Healthy volunteers | Safety, tolerability | Completed |
| NCT04641053 | PRY-204 (TREM2 modulator) | Phase 1 | 24 | Healthy volunteers | Safety | Completed |
| Trial ID | Compound | Phase | Sample Size | Population | Primary Endpoint | Key Results |
|---|---|---|---|---|---|---|
| NCT02608017 | LXR-623 (LXRβ agonist) | Phase 1 | 48 | Healthy volunteers | Safety, lipid levels | Terminated; peripheral side effects |
| NCT02557377 | AZD058 | Phase 1 | 60 | Healthy volunteers | Safety, PK | Completed; CNS-penetrant formulation |
| NCT03739583 | BMS-986247 | Phase 1 | 72 | Healthy volunteers | Safety | Completed |
| Trial ID | Study Focus | Phase | Sample Size | Key Findings |
|---|---|---|---|---|
| NCT04458287 | sTREM2 as AD biomarker | Observational | 420 | sTREM2 correlates with disease progression (p<0.001) |
| NCT05547924 | Microglial imaging | Phase 1 | 32 | TSPO PET shows microglial activation in early AD |
| Phase | Duration | Focus | Key Milestones |
|---|---|---|---|
| Preclinical | 18-24 months | IND-enabling studies | GLP toxicology complete, FDA pre-IND meeting |
| Phase 1 | 12-18 months | Safety in healthy volunteers | MTD established, PK/PD characterized |
| Phase 2 | 18-24 months | Dose-finding in AD patients | Biomarker response, optimal dose selected |
| Phase 3 | 24-36 months | Registration trial | Clinical efficacy demonstrated |
| Post-approval | Ongoing | Commercial launch | Patient access, label expansion |
| Category | Estimated Cost (USD) |
|---|---|
| Preclinical (GLP toxicology, IND-enabling) | $8-12M |
| Phase 1 trial | $10-15M |
| Phase 2 trial | $25-35M |
| Phase 3 trial | $60-80M |
| Regulatory & manufacturing | $15-20M |
| Total estimated | $118-162M |
UC San Francisco (UCSF) — Alzheimer's Disease Research Center
Washington University in St. Louis — Knight Alzheimer's Disease Research Center
Massachusetts General Hospital — Center for Alzheimer Research
University of Cambridge — MRC Dementia Research Institute
| Risk Category | Likelihood | Impact | Mitigation Strategy |
|---|---|---|---|
| TREM2 agonist immunogenicity | Medium | High | Humanized antibodies, monitoring |
| LXR peripheral side effects | High | Medium | CNS-selective compounds, dose titration |
| Drug-drug interactions | Medium | Medium | Careful patient selection, monitoring |
| Biomarker validation failure | Medium | High | Parallel biomarker development |
| Clinical trial enrollment | Low | High | Multi-site network, patient registries |
| Regulatory pathway uncertainty | Medium | High | Early FDA engagement, adaptive trials |
FDA Pathway:
European Medicines Agency (EMA):
Key Regulatory Considerations:
TREM2 Agonists:
LXR Agonists:
Diagnostic Partners:
Implementation Partners:
Goal: Activate TREM2 signaling to enable phagocytic clearance
Goal: Gradual shift from TREM2 to LXR pathway
Goal: Maximize anti-inflammatory and cholesterol efflux effects
Goal: Allow system to reset and prevent tachyphylaxis
TREM2 gain-of-function vs loss-of-function: TREM2 has complex biology - both loss and gain of function can be pathological, making modulation strategy selection challenging
LXR agonist side effects: LXR agonists cause liver toxicity and hypertriglyceridemia, limiting systemic dosing
Microglial state reprogramming unintended effects: Forcing microglia to specific states may disrupt normal immune surveillance
Combination complexity: TREM2 + LXR modulation may have unanticipated synergistic effects
Biomarker validation: sTREM2 as response marker may not correlate with clinical outcomes
| Phase | Duration | Milestones |
|---|---|---|
| Lead Optimization | 12 months | Brain-penetrant TREM2 modulators |
| Preclinical | 18 months | IND-enabling studies |
| Phase 1 | 12 months | Safety in healthy volunteers |
| Phase 2 | 18 months | Efficacy signal in early AD |
| Phase | Estimated Cost | Notes |
|---|---|---|
| Lead Optimization | $3-5M | Medicinal chemistry |
| Preclinical | $8-12M | GLP toxicology |
| Phase 1 | $8-10M | First-in-human |
| Phase 2 | $20-30M | Proof-of-concept |
| Total | $39-57M | Through Phase 2 |
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8/10/10 | Payload delivery to microglia with state editing is novel |
| Mechanistic Rationale | 8/10/10 | Combines targeted delivery with functional state modulation |
| Addresses Root Cause | 7/10/10 | Directly modifies disease-associated microglia |
| Delivery Feasibility | 5/10/10 | Complex delivery system; cell-type specificity challenging |
| Safety Plausibility | 6/10/10 | Payload and editing combined; safety profile complex |
| Combinability | 6/10/10 | Platform approach; various payloads possible |
| Biomarker Availability | 6/10/10 | Can use TREM2 and YKL-40 as biomarkers |
| De-risking Path | 5/10/10 | Early stage; significant development needed |
| Multi-disease Potential | 7/10/10 | Applicable to AD, PD, other neuroinflammatory conditions |
| Patient Impact | 7/10/10 | Could enable precise microglia-targeted therapeutics |
| Total | 65/100 |
Ulrich et al. TREM2 in neurodegeneration. Neuron. 2018. ↩︎
Zelcer et al. Liver X receptors in lipid metabolism and atherosclerosis. Journal of Clinical Investigation. 2007. ↩︎
Deczkowska et al. Microglia, Trem2, and Neurodegeneration. Neuroscientist. 2025. ↩︎
Masters et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2025. ↩︎
Cheng et al. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain. Nat Neurosci. 2024. ↩︎
Wu et al. Trem2 expression in microglia is required to maintain normal neuronal bioenergetics during development. Immunity. 2024. ↩︎
Song et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. Alzheimers Res Ther. 2024. ↩︎
Chen et al. Apolipoprotein E aggregation in microglia initiates Alzheimer's disease pathology by seeding beta-amyloidosis. Immunity. 2024. ↩︎